All Articles

Beyond the shower puff: Cleanlogic's new line embeds skincare into bath tools. But its exclusive Ulta launch is a masterclass in strategic growth.

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

Qorvo’s recent honor from Northrop Grumman is more than a trophy. It’s a look into the vital, innovative supply chains that truly power global security.

Kahuna Labs' new AI module analyzes support interactions to find hidden growth opportunities, transforming a reactive department into a strategic source of revenue.

o9 Solutions' promotion of an insider as COO isn't a simple C-suite shuffle. It's a clear signal of its ambition to move beyond AI tech to redefine how companies operate.

Dextra Partners' new VP isn't just a new hire; he's a signal. We deconstruct why firms are now hunting for 'full toolkit' talent to build resilient firms.

An agency's award win signals a seismic shift in online visibility. Beyond traditional SEO, a new strategy called GEO is delivering triple-digit growth by optimizing for AI.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

As rivals chase the novelty of an 'AI board member,' Indianapolis-based OnBoard is betting on a different future: one where AI serves human leaders.

By hiring top drug and deal makers, Bexorg signals its AI-powered human brain platform is ready to move from a bold experiment to a commercial powerhouse.

A Canadian firm hits record gas production in Uzbekistan, hailing a repeatable success model. But can it balance fossil fuel growth with its 'energy transition' identity?

Riverside Resources is spinning out Ravena Resources, replicating a strategy that launched two other public companies. Is this a blueprint for success?

Alarum Technologies faces an existential threat after FBI seizures. With a third of its staff cut and no answers, the company's future hangs in the balance.

A breakthrough study shows a wearable ear device can stimulate nerves to enhance the body’s natural clotting, offering a drug-free future for saving lives.

A new 891-acre luxury enclave is launching in Carmel with $6M+ homes. We unpack the project's complex history, its global financial backing, and what it signals.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

In a fluctuating private aviation market, Northern Jet's hiring of Ken Price signals a wider industry trend: human expertise is the ultimate asset.

As BNB Plus Corp. falls from Nasdaq to the over-the-counter markets, its hybrid crypto-biotech model is under intense scrutiny. What does this mean for investors?